Have a feature idea you'd love to see implemented?
Let us know!
KURA Kura Oncology Inc
Price (delayed)
$16.99
Market cap
$1.3B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.23
Enterprise value
$1.27B
Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable
Highlights
Kura Oncology's net income has decreased by 30% YoY and by 8% from the previous quarter
The debt is up by 28% year-on-year
Key stats
What are the main financial stats of KURA
Market
Valuations
Earnings
Shares outstanding
76.63M
Market cap
$1.3B
Enterprise value
$1.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$180.15M
EBITDA
-$179.28M
Free cash flow
-$154.85M
Per share
Balance sheet
Liquidity
EPS
-$2.23
Free cash flow per share
-$1.79
Book value per share
$6.12
Revenue per share
$0
TBVPS
$5.95
Total assets
$515.12M
Total liabilities
$49.05M
Debt
$16.73M
Equity
$466.07M
Working capital
$466.32M
Debt to equity
0.04
Current ratio
14.94
Quick ratio
14.69
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.5%
Return on equity
-40.4%
Return on invested capital
-40.5%
Return on capital employed
-37.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KURA stock price
How has the Kura Oncology stock price performed over time
Intraday
-2.19%
1 week
-7.01%
1 month
-15.93%
1 year
124.14%
YTD
18.15%
QTD
-13.05%
Financial performance
How have Kura Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$200.09M
Net income
-$181.75M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 35% YoY and by 9% QoQ
Kura Oncology's net income has decreased by 30% YoY and by 8% from the previous quarter
Growth
What is Kura Oncology's growth rate over time
Valuation
What is Kura Oncology stock price valuation
P/E
N/A
P/B
2.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 9% YoY and by 2.8% QoQ
The stock's P/B is 9% above its 5-year quarterly average of 2.6 and 5% above its last 4 quarters average of 2.7
The equity has contracted by 8% from the previous quarter
Efficiency
How efficient is Kura Oncology business performance
The return on equity has declined by 22% year-on-year and by 8% since the previous quarter
The ROA has contracted by 19% YoY and by 7% from the previous quarter
The return on invested capital has declined by 14% year-on-year and by 7% since the previous quarter
Dividends
What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KURA.
Financial health
How did Kura Oncology financials performed over time
KURA's total liabilities is up by 40% year-on-year
The quick ratio has contracted by 26% YoY and by 10% from the previous quarter
The debt is 96% smaller than the equity
The debt to equity has grown by 33% since the previous quarter and by 33% year-on-year
The debt is up by 28% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.